TNF in Melanoma Patients Treated With Immunotherapy
This trial is a translational proof-of-concept, open-label, prospective cohort study of 60
patients aiming to identify the clinical markers and/or biomarkers associated with
therapeutic response to immune checkpoints inhibitors, in patients with advanced melanoma.
The study will be conducted on a population of patients treated with ICI in the context of
routine care, separated in two subgroups:
- Subgroup 1: patients treated with anti-PD-1 alone (nivolumab or pembrolizumab)
- Subgroup 2: patients treated with the combined treatment anti-PD-1+anti-CTLA-4
(nivolumab + ipilimumab)
For each included patient, blood samples...